IRLAB Therapeutics AB (publ)
SSE:IRLAB-A.ST
14.45 (SEK) • At close February 20, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) SEK.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities: | ||||||||||
| Net Income
| -177.839 | -113.11 | 52.576 | -91.458 | -95.848 | -73.897 | -54.219 | -46.053 | -27.571 | -14.476 |
| Depreciation & Amortization
| 4.316 | 3.982 | 3.474 | 2.256 | 2.932 | 1.332 | 0.349 | 0.318 | 0.303 | 0.152 |
| Deferred Income Tax
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock Based Compensation
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change In Working Capital
| 8.627 | -33.985 | 34.296 | 0.183 | 1.959 | 1.977 | -1.908 | 4.215 | -0.264 | 3.173 |
| Accounts Receivables
| 3.619 | 3.634 | -12.811 | 2.62 | -3.778 | -2.6 | -1.057 | -0.806 | -0.21 | 1.687 |
| Inventory
| -5.008 | 37.619 | -47.107 | 2.437 | -5.737 | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables
| 5.008 | -37.619 | 47.107 | -2.437 | 5.737 | 4.577 | -0.851 | 5.021 | -0.054 | 0 |
| Other Working Capital
| 5.008 | -37.619 | 47.107 | -2.437 | 5.737 | 4.577 | -0.851 | 5.021 | -0.054 | 1.486 |
| Other Non Cash Items
| 0.005 | 0.501 | 38.295 | -0.195 | -0.244 | -0.202 | -1.963 | 0.702 | -0.123 | 0.127 |
| Operating Cash Flow
| -164.896 | -142.612 | 128.641 | -89.214 | -91.201 | -70.79 | -57.741 | -40.818 | -27.655 | -11.024 |
| Investing Activities: | ||||||||||
| Investments In Property Plant And Equipment
| -0.293 | -3.376 | -0.708 | -0.394 | -0.137 | -1.052 | -0.222 | -0.219 | 0 | 0 |
| Acquisitions Net
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 9.694 |
| Purchases Of Investments
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Sales Maturities Of Investments
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activites
| 0 | -0.5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow
| -0.293 | -3.376 | -0.708 | -0.394 | -0.137 | -1.052 | -0.222 | -0.219 | 0 | 9.694 |
| Financing Activities: | ||||||||||
| Debt Repayment
| -23.686 | -3.134 | -2.865 | -1.616 | -1.547 | 0 | -0.4 | -1.483 | -1.483 | -1.893 |
| Common Stock Issued
| 2.771 | 0 | -0.18 | 275.495 | 68.97 | 131.575 | 107.336 | 53.832 | 23.895 | 22.89 |
| Common Stock Repurchased
| 0 | 0 | -0.18 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities
| 20.905 | -3.134 | -0.18 | -17.788 | -1.547 | 131.575 | -0.4 | -1.483 | -1.483 | -1.893 |
| Financing Cash Flow
| 23.687 | -3.134 | -3.045 | 256.091 | 67.423 | 131.575 | 106.936 | 52.349 | 22.412 | 20.997 |
| Other Information: | ||||||||||
| Effect Of Forex Changes On Cash
| 0.035 | 0.001 | 0 | -0.001 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Change In Cash
| -141.467 | -149.121 | 124.888 | 166.482 | -23.915 | 59.733 | 48.973 | 11.312 | -5.243 | 19.667 |
| Cash At End Of Period
| 111.309 | 252.776 | 401.897 | 277.009 | 110.527 | 134.442 | 74.709 | 25.736 | 14.424 | 19.667 |